Literature DB >> 16512320

The long-term health and economic benefits of DOTS implementation in Ecuador.

Olivia Oxlade1, Judyth Vaca, Elizabeth Romero, Kevin Schwartzman, Brian Graham, Lucero Hernandez, Terry Tannenbaum, Dick Menzies.   

Abstract

BACKGROUND: Between April 2001 and March 2004, the Directly Observed Therapy-Short course (DOTS) program was successfully implemented by the National Tuberculosis control program, with assistance from the Canadian Lung Association, in three provinces of Ecuador, where 52% of the population of the country reside.
METHODS: Markov modelling was used to project TB-related morbidity, mortality and costs if the former TB control program (status quo) had continued or if the newly expanded DOTS program is maintained over 20 years. Extensive sensitivity analyses were used to determine the effect on projected outcomes of varying key assumptions.
RESULTS: If DOTS is maintained over the next 20 years, we predict that 18,760 cases and 15,812 TB-related deaths will be prevented, resulting in societal savings of dollars 203 million and government savings of dollars 7.1 million (all costs in dollars US). These findings were robust in extensive sensitivity analyses. Given the initial investment of dollars 3 million for DOTS implementation, this would mean a cost of dollars 190 per life saved.
CONCLUSIONS: Implementation of DOTS could yield very substantial public health and economic benefits for Ecuador. These results demonstrate the benefits from Canadian government support for DOTS implementation in low- and middle-income countries.

Entities:  

Mesh:

Year:  2006        PMID: 16512320      PMCID: PMC6976271     

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  17 in total

1.  Increasing transparency in partnerships for health--introducing the Green Light Committee.

Authors:  Rajesh Gupta; J Peter Cegielski; Marcos A Espinal; Myriam Henkens; Jim Y Kim; Catherina S B Lambregts-Van Weezenbeek; Jong-Wook Lee; Mario C Raviglione; Pedro G Suarez; Francis Varaine
Journal:  Trop Med Int Health       Date:  2002-11       Impact factor: 2.622

2.  DOTS implementation in a middle-income country: development and evaluation of a novel approach.

Authors:  J Vaca; H Peralta; L Gresely; R Cordova; D Kuffo; E Romero; T N Tannenbaum; S Houston; B Graham; L Hernandez; D Menzies
Journal:  Int J Tuberc Lung Dis       Date:  2005-05       Impact factor: 2.373

3.  Domestic returns from investment in the control of tuberculosis in other countries.

Authors:  Kevin Schwartzman; Olivia Oxlade; R Graham Barr; Franque Grimard; Ivelisse Acosta; Jeannette Baez; Elizabeth Ferreira; Ricardo Elías Melgen; Willy Morose; Arturo Cruz Salgado; Vary Jacquet; Susan Maloney; Kayla Laserson; Ariel Pablos Mendez; Dick Menzies
Journal:  N Engl J Med       Date:  2005-09-08       Impact factor: 91.245

4.  Does DOTS work in populations with drug-resistant tuberculosis?

Authors:  Kathryn DeRiemer; Lourdes García-García; Miriam Bobadilla-del-Valle; Manuel Palacios-Martínez; Areli Martínez-Gamboa; Peter M Small; José Sifuentes-Osornio; Alfredo Ponce-de-León
Journal:  Lancet       Date:  2005 Apr 2-8       Impact factor: 79.321

Review 5.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

6.  Gender difference in delays to diagnosis and health care seeking behaviour in a rural area of Nepal.

Authors:  M Yamasaki-Nakagawa; K Ozasa; N Yamada; K Osuga; A Shimouchi; N Ishikawa; D S Bam; T Mori
Journal:  Int J Tuberc Lung Dis       Date:  2001-01       Impact factor: 2.373

7.  Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South Africa.

Authors:  K Floyd; D Wilkinson; C Gilks
Journal:  BMJ       Date:  1997-11-29

8.  Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Lilongwe District, Malawi.

Authors:  K Floyd; J Skeva; T Nyirenda; F Gausi; F Salaniponi
Journal:  Int J Tuberc Lung Dis       Date:  2003-09       Impact factor: 2.373

9.  The effect of tuberculosis control in China.

Authors: 
Journal:  Lancet       Date:  2004 Jul 31-Aug 6       Impact factor: 79.321

10.  Scale up: meeting targets in global tuberculosis control.

Authors:  Gijs Elzinga; Mario C Raviglione; Dermot Maher
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

View more
  1 in total

1.  The road to tuberculosis treatment in rural Nepal: A qualitative assessment of 26 journeys.

Authors:  Augustinus H A Ten Asbroek; Merijn W Bijlsma; Puspha Malla; Binjwala Shrestha; Diana M J Delnoij
Journal:  BMC Health Serv Res       Date:  2008-01-11       Impact factor: 2.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.